Patients

Information for patients

This website is intended for US patients undergoing allogeneic stem cell transplantation in acute myeloid leukemia (AML) and their families. It provides information about the causes of graft-versus-host disease and its prevention by ex vivo T cell depletion.

Note: Are some of the words or abbreviations unfamiliar to you? Definitions of all words marked in bold can be found in the glossary.

This website is not intended to replace conversations with your healthcare team. Your doctor and other healthcare providers are the most valuable resources for answering questions about your disease and ex vivo T cell depletion as method for graft-versus-host disease prophylaxis.

Background information

What is AML?

AML is a type of blood cancer. There are three main types of cells in the blood: red blood cells, white blood cells, and platelets. Normally, white blood cells are responsible for fighting infections and other diseases

What is allogenic stem cell transplantation?

Autologous stem cell transplantation may be used as a consolidation therapy. However, allogenic stem cell transplantation is considered to be the best curative treatment option for some AML patients.

What is GvHD?

Although allogeneic stem cell transplantation is a potentially curative treatment option for AML, it is also associated with the risk of several serious side effects. One major complication is a disease called GvHD.

Glossary

Are some of the words or abbreviations unfamiliar to you? Definitions of all words marked in bold can be found in the glossary.

Contact information for patients

Humanitarian Device
Authorized by U.S. Federal Law for use in the treatment of patients with acute myeloid leukemia (AML) in first complete remission. The effectiveness of the device for this use has not been demonstrated.

Indications for Use
The CliniMACS® CD34 Reagent System is indicated for processing hematopoietic progenitor cells collected by apheresis (HPC, Apheresis) from an allogeneic, HLA-identical, sibling donor to obtain a CD34+ cell-enriched population for hematopoietic reconstitution following a myeloablative preparative regimen without the need for additional graft versus host disease (GVHD) prophylaxis in patients with acute myeloid leukemia (AML) in first morphologic complete remission.

Contraindications
Do not use CD34+ cells prepared with CliniMACS CD34 Reagent System in patients with known hypersensitivity to murine (mouse) proteins or iron dextran.

Rx only